IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RUSNATI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.964
EU - Europa 8.266
AS - Asia 7.742
SA - Sud America 1.367
AF - Africa 185
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 17
Totale 32.584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.714
PL - Polonia 3.414
CN - Cina 2.656
SG - Singapore 2.629
UA - Ucraina 1.299
BR - Brasile 1.146
HK - Hong Kong 819
IT - Italia 776
DE - Germania 764
VN - Vietnam 559
FI - Finlandia 451
GB - Regno Unito 379
FR - Francia 376
TR - Turchia 262
IN - India 233
RU - Federazione Russa 230
IE - Irlanda 221
BD - Bangladesh 156
CA - Canada 124
AR - Argentina 82
ID - Indonesia 79
MX - Messico 74
NL - Olanda 73
ZA - Sudafrica 66
IQ - Iraq 60
CZ - Repubblica Ceca 51
JP - Giappone 51
SE - Svezia 48
AU - Australia 41
AT - Austria 36
EC - Ecuador 36
ES - Italia 36
PK - Pakistan 34
MA - Marocco 30
BE - Belgio 26
CO - Colombia 25
KE - Kenya 25
UZ - Uzbekistan 24
CL - Cile 22
IR - Iran 22
VE - Venezuela 20
SA - Arabia Saudita 19
JM - Giamaica 18
JO - Giordania 16
AE - Emirati Arabi Uniti 15
CH - Svizzera 14
EU - Europa 14
AZ - Azerbaigian 13
IL - Israele 13
LT - Lituania 13
PE - Perù 13
KZ - Kazakistan 12
NG - Nigeria 12
EG - Egitto 11
MU - Mauritius 9
MY - Malesia 9
PY - Paraguay 9
PA - Panama 8
UY - Uruguay 8
BG - Bulgaria 7
DZ - Algeria 7
PT - Portogallo 7
TN - Tunisia 7
EE - Estonia 6
KR - Corea 6
LK - Sri Lanka 6
NP - Nepal 6
OM - Oman 6
KG - Kirghizistan 5
LB - Libano 5
LV - Lettonia 5
SN - Senegal 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
NO - Norvegia 4
TW - Taiwan 4
AL - Albania 3
CY - Cipro 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
MD - Moldavia 3
PH - Filippine 3
PS - Palestinian Territory 3
RO - Romania 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
GF - Guiana Francese 2
GT - Guatemala 2
IS - Islanda 2
SI - Slovenia 2
SV - El Salvador 2
ZW - Zimbabwe 2
Totale 32.557
Salva come PNG Salva come JPEG
Città #
Warsaw 3.405
Fairfield 1.667
Ashburn 1.303
Woodbridge 1.275
Singapore 1.233
Jacksonville 957
Houston 899
Hong Kong 816
Cambridge 711
San Jose 651
Ann Arbor 605
Wilmington 600
Seattle 580
Beijing 567
Chandler 503
The Dalles 449
Princeton 397
Nanjing 348
New York 315
Dallas 295
Helsinki 244
Los Angeles 235
Dublin 215
Lauterbourg 204
Istanbul 186
Dearborn 154
Ho Chi Minh City 151
Brescia 148
Council Bluffs 147
Nanchang 125
Dong Ket 122
Munich 114
São Paulo 114
Milan 110
Buffalo 99
Moscow 98
Hanoi 97
San Francisco 92
San Diego 88
Des Moines 86
Shenyang 84
Jinan 82
Changsha 80
Chicago 76
Hebei 74
Boardman 72
Santa Clara 71
Redondo Beach 70
Tianjin 68
Jiaxing 65
Lancaster 63
Shanghai 62
London 61
Orem 59
Hangzhou 53
Phoenix 52
Brooklyn 50
Jakarta 46
Kunming 46
Tokyo 44
Toronto 42
Atlanta 41
Verona 40
Rome 38
Johannesburg 36
Guangzhou 35
Rio de Janeiro 34
Augusta 32
San Mateo 32
Porto Alegre 31
Belo Horizonte 30
Chennai 30
Manchester 30
Montreal 30
Denver 29
Zhengzhou 29
Frankfurt am Main 28
Nuremberg 28
Turku 28
Brno 27
Haikou 27
Lanzhou 27
Ningbo 26
Leawood 25
Amsterdam 24
Kocaeli 24
Mexico City 24
Brussels 23
Norwalk 22
Poplar 22
Charlotte 21
Curitiba 21
Mumbai 21
Nairobi 21
Olomouc 21
Dhaka 20
Parma 20
Tashkent 20
Boston 19
Brasília 19
Totale 22.780
Salva come PNG Salva come JPEG
Nome #
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 385
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system 371
Bridging the past and the future of virology: Surface plasmon resonance as a powerful tool to investigate virus/host interactions. 363
Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use 319
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. 315
Biological role of immunoglobulin Free light chains interactomes 310
Membrane association of peroxiredoxin-2 in red cells is mediated by n-terminal cytoplasmic domain of band 3 309
BSA conjugates bearing multiple copies of the basic domain of HIV-1 Tat: prototype for the development of multitarget inhibitors of extracellular Tat 308
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. 304
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric Ligands 291
Highly Sulfated K5 Escherichia coli Polysaccharide Derivatives Inhibit Respiratory Syncytial Virus Infectivity in Cell Lines and Human Tracheal-Bronchial Histocultures. 290
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance 284
Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance 279
Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin. 278
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. 278
Ruolo dell’eparina e dei proteoglicani eparan solfati nella modulazione dell’angiogenesi indotta dal fattore di crescita basico dei fibroblasti 274
Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. 272
Pradamicin A: a new therapeutic concept for tretment of virus infections with a glycosilated envelope such as human immunodeficiency virus 260
Inhibition of Non Canonical HIV-1 Tat Secretion Through the Cellular Na+,K+-ATPase Blocks HIV-1 Infection 260
Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors 258
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library 254
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 251
A complex of α(6) integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. 247
Role of the soluble pattern recognition receptor PTX3 in vascular biology. 247
The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice 244
The FGF2-binding domain of thrombospondin-1: functional characterization and exploitation to design antiangiogenic compounds 242
Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. 238
Functionalization of gold surfaces with copoly(DMA-NAS-MAPS) by dip coating: Surface characterization and hybridization tests 232
Sialic acid associated to αvβ3 integrin mediates HIV-1 Tat interaction and endothelial cell proangiogenic activation. 229
Chemoselective surface immbolization of proteins through a cleavable peptide 224
The agmatine-containing poly(Amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses 221
Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins 220
Integrin {alpha}V{beta}3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo. 216
Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin: IDENTIFICATION OF THE HEPARIN-BINDING MOTIF OF p17 AS A TARGET FOR THE DEVELOPMENT OF MULTITARGET ANTAGONISTS 216
A distinct basic fibroblast growth factor (FGF-2/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells 207
Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. 207
Fibroblast growth factor-2 antagonist and Antiangiogenic activity of long-pentraxin 3-derived synthetic peptides 202
A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity 202
A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: Implications for EBV-driven lymphomagenesis in the HIV setting. 201
Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. 201
Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. 196
Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. 196
alphav/beta3 Integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF2) in cultured endothelial cells 191
Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes 191
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. 189
Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis 187
Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. 186
Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational studies, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue 185
Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. 181
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach 181
Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2 177
A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. 177
Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. 177
Sialic acid as a target for the development of novel antiangiogenic strategies 175
A mutant of basic fibroblast growth factor that has lost the ability to stimulate plasminogen activator synthesis in endothelial cells. 172
Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications 171
Upregulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx 167
Basic fibroblast growth factor expression in endothelial cells: an autocrine role in angiogenesis? 166
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 166
Autocrine role of basic fibroblast growth factor (bFGF) in angiogenesis and angioproliferative diseases 160
The colloidal side of cell communication. 160
Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable" 159
Subcellular localization and biological activity of a Mr 18,000 basic fibroblast growth factor: site directed mutagenesis of a putative nuclear translocation sequence 159
HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation 158
Distinct role of 2-O, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1 157
Cutting edge: proangiogenic properties of alternatively activated dendritic cells. 156
Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. 155
Human basic fibroblast growth factor: structure- function relationship of an angiogenic molecule 155
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 154
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 154
Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway 153
alpha v beta 3 integrin-dependent activation of focal adhesion kinase mediates NF-kB activation and motogenic activity by HIV-1 Tat in endothelial cells 149
Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures 148
Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity 148
Cell membrane GM1 ganglioside is a functional co-receptor for Fibroblast growth factor-2. 148
Purification of basic fibroblast growth factor from rat brain: identification of a Mr 22,000 immunoreactive form. 146
The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2) 145
A monoclonal antibody to the NH2-terminal region of HuIFN inhibits the antiproliferative activity of the lymphokine without affecting its internalization 144
Biochemical bases of the interaction of the human basic fibroblast growth factor with glycosaminoglycans: new insights from trypsin digestion studies 144
HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2 144
Fibroblast growth factor-2 in angiogenesis 143
Plasmonic exosomes for enhanced monitoring of monoclonal gammopathies 143
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 142
Heparin derivatives as angiogenesis inhibitors 138
Dendritic cell-endothelial cell cross-talk in angiogenesis. 138
Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region. 138
Liver DNA damage by chemical carcinogens: role of thyroid hormones 138
Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases 137
Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis 136
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 135
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. 134
Targeting fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis 134
Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. 134
The Impact of Surface Plasmon Resonance in Virology 134
Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors 133
Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans 132
Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides 132
Sulfated K5 Escherichia coli polysaccharide derivatives as wide range inhibitors of genital types of human papillomavirus 131
Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds 131
Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells: an in vitro autocrine model of angiogenesis in brain tumors 131
Totale 19.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.933
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.933
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021216 0 0 0 0 0 0 0 0 0 0 0 216
2021/20221.785 93 423 30 43 24 69 123 119 84 235 141 401
2022/20231.409 219 59 56 93 106 382 9 149 198 18 48 72
2023/20241.549 93 30 137 68 67 235 52 69 403 49 40 306
2024/20253.988 47 23 18 493 356 286 279 125 350 461 948 602
2025/20268.942 824 1.167 829 1.315 805 602 1.301 317 579 736 268 199
Totale 33.016